Integra Life Sciences (IART) commenced 2025 with a new CEO. She hasn’t had a dream start.
Integra reported Q1 2025 results on 5 May.
Organic revenue declined by 3.5%, margins were down and operating cash flow was negative $11.3m.
The Tissue Technologies segment revenue saw a 9% decline on both reported and organic basis. The Wound Reconstruction and Care division had revenue of $74.8m, down from $80.9m in Q1 24 and $100.9m in Q1 23.
Reported GAAP gross margin was 50.8%, compared to 56.1% in Q1 2024.
The immediate outlook isn’t great either.
Second quarter revenue guidance is for a year-over-year decline of 4.4% to 6.8%.
Tariffs now present as a further problem. The impact of tariffs in 2025 is estimated to be $22m.
The market was seriously unimpressed. Following a 21.1% drop in share price on the same day, Integra now has several law firms investigating whether the Company has issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Prior to Q4 2024 results being released in February, IART was trading at ~ $26. Following Q1 2025 results being released this month, the share price dropped to a low of $12.25.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)